PAF C-18, a naturally derived phospholipid, is produced via 'remodeling' and 'de novo' pathways upon stimulation. While less potent than PAF C-16 in platelet aggregation, it's equally effective in activating guinea pig macrophages. PAF C-18 triggers the release of PGE 2 and TXB 2 from stimulated macrophages and enhances their spreading. Pathological processes linked to PAF include necrotizing enterocolitis, inflammation, asthma, and allergy.
